导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.50% | 1392/4773 |
| 近一周 | -1.25% | 1890/5465 |
| 近一月 | -8.46% | 4949/5421 |
| 近一季 | -18.75% | 4808/5231 |
| 近半年 | -0.21% | 1434/4920 |
| 近一年 | 8.65% | 1297/4394 |
| 近两年 | 119.63% | 437/2954 |
| 近三年 | 70.61% | 345/2253 |
| 成立以来 | 207.23% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.57% 1857/4961 |
36.91% 872/5312 |
- - |
- - |
| 2025 | 50.98% 454/4813 |
-1.61% 2708/3635 |
3.25% 1079/4076 |
50.00% 324/4524 |
-0.92% 2718/4813 |
| 2024 | 14.33% 1056/3463 |
-3.94% 1584/2808 |
-6.46% 1957/3014 |
29.15% 172/3129 |
-1.47% 1716/3463 |
| 2023 | -18.81% 1829/2656 |
2.08% 1452/2280 |
-7.16% 1792/2385 |
-9.38% 1805/2515 |
-5.46% 1365/2655 |
| 2022 | -28.73% 1577/2207 |
-19.71% 1488/1919 |
6.08% 771/2016 |
-18.35% 1698/2113 |
2.49% 921/2208 |
| 2021 | 14.66% 325/1822 |
-6.43% 1002/1255 |
26.97% 64/1330 |
-5.99% 889/1466 |
2.66% 540/1822 |
| 2020 | 68.13% 83/1250 |
3.88% 104/1028 |
30.55% 51/1067 |
7.29% 791/1164 |
15.55% 200/1184 |
| 2019 | 42.81% 204/1092 |
34.46% 114/754 |
-10.19% 727/804 |
7.49% 85/850 |
10.03% 169/918 |
| 2018 | -29.99% 460/834 |
- - |
- - |
- - |
-13.23% 517/691 |
| 2017 | 28.81% 71/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.55% 221/605 |
- - |
- - |
- - |
- - |
| 2015 | 24.67% 94/575 |
- - |
- - |
- - |
- - |
| 2014 | 50.09% 84/237 |
- - |
- - |
- - |
- - |
| 2013 | -3.35% 77/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.76% 109/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时创业板ETF VS. 长安沪深300非周期A(740101) |